Ventfort
Research OnlyA cytamin-class peptide supplement derived from blood vessel tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for vascular health support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Vascular cytamin · Blood vessel peptides · A-14 vascular peptides
Preclinical evidence only
- Preclinical
- 83%
- Clinical
- 0%
Based on 6 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 13: 1A animal-only (2 animal + 1 cell study on an undefined blood-vessel tissue cytamin, no human data) = 6; 1B 0 (no RCT, high RoB); 1C 2 (human N=0); 1D 2 (indirect surrogate, oral undefined mixture); 1E 3 (modest single-source preclinical program). Mechanism 28: 2A 10 (target inferred only — Ventfort is an undefined peptide complex, no named target with binding data); 2B 8 (proximal Khavinson peptide gene-regulation framework partially mapped by analogy); 2C 2 (no dose-response data); 2D 8 (effects asserted in animal models). Plausibility 45: 3A 8 (large speculative leap — oral undefined mixture to vascular benefit, oral peptide bioavailability unproven); 3B 14 (coherent with but not strongly supported by vascular biology); 3C 12 (class analogy — related Khavinson vascular dipeptide EW preserves endothelium-dependent relaxation / inhibits ACE2, PMID 37686182); 3D 11 (tightly scoped single vascular claim). Global Coverage 14: 4A 4 + 4B 5 + 4C 5 (all from one Russian group, one country, <5 Ventfort-specific studies) + 4D 0 (no national drug-regulator approval; Russian supplement only). Community Experience 20: 5A 3 + 5B 6 + 5C 3 + 5D 8 (negligible documented use, no recurring adverse signal over limited exposure). Overall 24 = preliminary. Effectiveness not-established: no quantified human efficacy estimate and no meaningful community effect signal (dossier reports no user reports). Sits just above sibling cytamin cerluten (19) — no human data here vs cerluten's 1 observational study, but marginally stronger vascular class-analogy support.
Mechanism of Action
Ventfort is a cytamin-class supplement containing peptide complexes derived from blood vessel tissue.
Proposed Mechanisms
- Endothelial Support - Claimed to support blood vessel lining function
- Vascular Tone - Proposed effects on vessel elasticity
- Cardiovascular Health - Marketed for overall vascular support
Important Limitations
- NOT a defined peptide - contains complex mixture
- Oral peptide bioavailability is generally very low
- No Western clinical validation
- No randomized controlled trials
- NOT a treatment for cardiovascular disease
- Not approved by any Western regulatory agency
Vesugen
CompatibleBoth target vascular function - Vesugen is synthetic KED tripeptide, Ventfort is tissue-derived cytamin supplement.
Cardiogen
CompatibleBoth target cardiovascular system - Cardiogen for heart, Ventfort for blood vessels.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Ventfort
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01 · Evaxion EVX-01 · AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1/2 data in melanoma showed a 67% objective response rate (8/12; 6 partial, 2 complete) when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.